Public health surveillance stratifies populations into age groups to help identify threats and provide appropriate responses. However, there is considerable variation in the age groupings used for epidemiology both between and within countries. We evaluate the age groups (under 1, 1-4, 5-14, 15-44, 45-64, over 65 years) used for syndromic surveillance in England. Comparing the existing age grouping with alternatives and using syndromic data to suggest new age groupings that maximise the homogeneity within groups and heterogeneity between groups. Data between November 2011 and March 2024 was extracted from four syndromic systems including 79 different syndromic indicators. Correlations between time series for individual ages in years were used to calculate homogeneity of specific age groups and age groupings (collections of age groups that completely span 0 to 90 years). Young adolescents were identified as a specific age group with distinct trends different to younger children or older adolescents. The current age group of 5 to 14 years was found to be more heterogeneous that over age groups, even those with a much wider span. Also, the age group over 65 years was assessed to be too broad and would benefit from being split into those over 90 years and below. Thus, our recommendation is a new age grouping for syndromic surveillance consisting of under 1s, 1 to 4, 5 to 8, 9 to 17, 18 to 33, 34 to 50, 51 to 67, 68 to 89 and over 90 years.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Only publically available aggregated surveillance data were used for this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors